Recurrence of sarcoidosis following interferon alpha therapy for chronic hepatitis C

Internal Medicine

Volumn 35, Issue 5, 1996, Pages 376-379

  Nakajima, Masamitsu ^a   Kubota, Yoshifumi ^a   Miyashita, Naoyuki ^a   Niki, Yoshihito ^a   Matsushima, Toshiharu ^a   Manabe, Toshiaki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

granuloma; IFN ; soluble IL 2

Indexed keywords

ALPHA INTERFERON; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 2 RECEPTOR; PREDNISOLONE;

AGED; ARTICLE; CASE REPORT; GRANULOMA; HEPATITIS C; HUMAN; LUNG SARCOIDOSIS; MALE; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE;

EID: 0029975712     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.35.376     Document Type: Article

References (20)

1. Schattner A. Review; Interferon and autoimmunity. Am J Med Sci 295: 532, 1988.
2. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl-NI, Decker JL, Notkins AL. Immune Interferon in the circulation of patients with autoimmune disease. N Engl J Med 301: 5, 1979.
3. Davis GL, Balart LA, Schiff ER. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 321: 1501, 1989.
4. Yuki N, Hayashi N, Hagiwara H, et al. Quantitative analysis of antibodies to hepatitis C virus during interferon-alpha therapy. Hepatology 17:960, 1993.
5. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 4: 234, 1986.
6. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68: 1536, 1991.
7. Peters M. Mechanism of action of interferon. Semin Liver Dis 9: 235, 1989.
8. Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 63: 1086, 1986.
9. Abdi EA, Venner PM. Immune thrombocytopenia after α-interferon therapy in patients with cancer. JAMA 255: 1878, 1986.
10. Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 59: 896, 1987.
11. Liozon E, Cransac M, Remenieras L, Cathy-Thomas I, Vovor A, Bordessoule D. La Sarcoïdose: Une nouvelle complication de traitement par I'interféron alpha. La Revue de Medecine Interne 14 (S462): 1160, 1993 (in French with English abstract).
12. Blum L, Serfaty L, Wattiaux MJ, Picard O, Cabane J, Imbert JC. Nodules hypodermiques sarcoïdosiques au cours d'une hépatite virale C traitée par Interféron alpha 2b. La Revue de Medecine Interne 14 (S462): 1161, 1993 (in French with English abstract).
13. Baughman RP. Sarcoidosis, usual and unusual manifestations. Chest 94: 165, 1988.
14. Moseley PL, Hemken C, Monick M, Nugent K, Hunninghake GW. Interferon and growth factor activity for human lung fibroblasts: release from bronchoalveolar cells from patients with active sarcoidosis. Chest 89: 657, 1986.
15. Robinson BWS, Rose AH. Pulmonary gamma interferon production in patient with fibrosing alveolitis. Thorax 45: 105, 1990.
16. Asano M, Minagawa T, Ohmichi M, Hiraga Y. Detection of endogenous cytokines in sera or in lymph nodes obtained from patients with sarcoidosis. Clin Exp Immunol 84: 92, 1991.
17. Amaya M, Shijubo N, Fujii N, Oguma K, Abe S. Oligo-2′,5′-Adenylate synthetase in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 105: 496, 1994.
18. Siltzbach LE. Current thoughts on the epidemiology and etiology of sarcoidosis. Am J Med 39: 361, 1965.
19. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann NY Acad Sci 278: 321, 1976.
20. Murray HW: Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 108: 595, 1988.